Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

for the Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team

Research output: Contribution to journalArticlepeer-review

Abstract

We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with a variant vaccine did not increase the magnitude or the durability of the serological responses compared to a single variant vaccine boost.

Original languageEnglish (US)
Pages (from-to)1662-1666
Number of pages5
JournalJournal of Infectious Diseases
Volume228
Issue number12
DOIs
StatePublished - Dec 15 2023
Externally publishedYes

Keywords

  • SARS-CoV-2
  • vaccine
  • variant

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial'. Together they form a unique fingerprint.

Cite this